Skip to main content
. 2021 Dec 17;25(2):59. doi: 10.3892/mmr.2021.12575

Figure 4.

Figure 4.

Suppression of RANKL-induced JNK signalling by ZOL. (A) RAW264.7 osteoclast precursors treated with RANKL for 30 min following pre-treatment with ZOL (0, 0.1, 1, or 5 µM) for 4 h. Band intensity ratios of (B) p-ERK/ERK, (C) p-p38/p38 and (D) p-JNK/JNK. #P<0.05 vs. vehicle group; *P<0.05 and **P<0.01 vs. RANKL-only group. ZOL, zoledronic acid; RANKL, receptor activator of nuclear factor-κB ligand; JNK, c-Jun N-terminal kinase; ERK1/2, extracellular regulated protein kinases.